University of Colorado Cancer Center NCI-Designated Comprehensive Cancer Center | Strategic Alliance Partners

October 31, 2024

Manali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

October 23, 2024

Drs Camidge and Ney discuss Dr Ney’s journey to becoming a neurologic oncologist and his experience as a physician with Tourette syndrome.

September 13, 2024

Breelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.

August 28, 2024

Manali Kamdar, MD, discusses which populations of lymphoma subtypes, such as MCL, may derive the most benefit from liso-cel treatment.

August 13, 2024

Manali Kamdar, MD, discusses responses with liso-cel according to prior lines of therapy and BTK inhibitor exposure in mantle cell lymphoma.

August 08, 2024

The Colorado School of Public Health announces the launch of WeCanWork, a program to provide support to cancer patients as they balance work and treatment.

July 11, 2024

Recent studies of novel mTOR inhibitors in combination with various agents have shown how these combinations may be used for patients with solid tumors.

July 05, 2024

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

July 01, 2024

Manali Kamdar, MD, discusses the patient population included in the mantle cell lymphoma cohort of the phase 3 TRANSCEND NHL 001 trial.

May 29, 2024

The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.

May 29, 2024

Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.

May 22, 2024

The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.

May 22, 2024

D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

May 15, 2024

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

May 15, 2024

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

May 13, 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

May 10, 2024

Bradley R. Corr, MD, discusses a phase 2 study evaluating rucaparib maintenance therapy in patients with metastatic and recurrent endometrial cancer.

May 08, 2024

Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.

May 08, 2024

Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.

May 01, 2024

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.